微盟(02013.HK)吐逾6%考驗20天線 擬發1.5億美元CB
微盟集團(02013.HK)擬發1.5億美元CB,該股繼昨天續升至6.13元逾兩個月高位遇壓後,今天扭兩連漲兼失守10天線(5.83元),考驗20天線(5.56元),最低見5.51元,現造5.56元,回吐6.4%,成交進一步增至1.07億股,同創逾兩個月高,涉資6.12億元。
微盟公布,建議發行1.5億美元2025年到期年息1.5%有擔保可換股債券(CB),初步換股價6.72元(較昨天收市價折讓近13%),料所得款項淨額1.47億美元,將用於提升綜合研發實力、升級營銷系統、建立產業基金及補充營運資金等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.